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A B S T R A C T
Objective: Supported in the Hippocratic aphorism primum non nocere, the bioethical principle 
of non-maleficence pray that the medical act cause the least damage or injury to the health 
of the patient, leaving it to the doctor to assess the risks of a particular therapy through 
knowledge of possible adverse events of drugs. Among these, the rebound effect represents 
a common side effect to numerous classes of modern drugs, may cause serious and fatal 
disorders in patients. This review aims to clarify the health professionals on clinical and 
epidemiological aspects of rebound phenomenon.
Methods: A  qualitative, exploratory and bibliographic review was held in the PubMed 
database using the keywords ‘rebound’, ‘withdrawal’, ‘paradoxical’, ‘acetylsalicylic acid’, 
‘anti-inflammatory’, ‘bronchodilator’, ‘antidepressant’, ‘statin’, ‘proton pump inhibitor’ and 
‘bisphosphonate’.
Results: The rebound effect occurs after discontinuation of numerous classes of drugs that 
act contrary to the disease disorders, exacerbating them at levels above those prior to 
treatment. Regardless of the disease, the drug and duration of treatment, the phenomenon 
manifests itself in a small proportion of susceptible individuals. However, it may cause 
serious and fatal adverse events should be considered a public health problem in view of 
the enormous consumption of drugs by population.
Conclusion: Bringing together a growing and unquestionable body of evidence, the physician 
needs to have knowledge of the consequences of the rebound effect and how to minimize 
it, increasing safety in the management of modern drugs. On the other hand, this rebound 
effect can be used in a curative way, broadening the spectrum of the modern therapeutics.
© 2012 Elsevier Editora Ltda. 
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Efeito rebote dos fármacos modernos: evento adverso grave 
desconhecido pelos profissionais da saúde
R E S U M O
Objetivo: Apoiado no aforismo hipocrático primum non nocere, o princípio bioético da não 
maleficência roga que o ato médico cause o menor dano ou agravo à saúde do paciente, 
incumbindo ao médico avaliar os riscos de determinada terapêutica por meio do 
conhecimento dos possíveis eventos adversos das drogas. Dentre esses, o efeito rebote 
representa um efeito colateral comum a inúmeras classes de fármacos modernos, podendo 
causar transtornos graves e fatais nos pacientes. Esta revisão tem o objetivo de esclarecer 
os profissionais da saúde sobre os aspectos clínicos e epidemiológicos do fenômeno rebote.
Métodos: Uma revisão qualitativa, exploratória e bibliográfica foi realizada na base de dados 
PubMed utilizando os unitermos ‘rebound’, ‘withdrawal’, ‘paradoxical’, ‘acetylsalicylic acid’, 
‘anti-inflammatory’, ‘bronchodilator’, ‘antidepressant’, ‘statin’, ‘proton pump inhibitor’ and 
‘bisphosphonate’.
Resultados: O efeito rebote ocorre após a descontinuação de inúmeras classes de fármacos 
com ação contrária aos distúrbios da doença, exacerbando-os a níveis superiores aos 
anteriores do tratamento. Independente da doença, da droga e da duração do tratamento, 
o fenômeno se manifesta numa pequena proporção de indivíduos suscetíveis. No entanto, 
pode causar eventos adversos graves e fatais, devendo ser considerado um problema de 
saúde pública em vista do enorme consumo de fármacos pela população.
Conclusão: Reunindo um corpo de evidências crescente e inquestionável, o médico precisa 
ter conhecimento das consequências do efeito rebote e de como minimizá-lo, desse modo 
aumentando a segurança no manejo das drogas modernas. Por outro lado, este efeito 
rebote pode ser utilizado de forma curativa, ampliando o espectro da terapêutica moderna.
Introduction
According to Webster’s New World Medical Dictionary,1 
“rebound” is defined as “the reversal of a response upon the 
withdrawal of a stimulus”, while “rebound effect” is “the 
increased production of negative symptoms when the effect 
of a drug has passed or the patient no longer responds to the 
drug. If a drug produces a rebound effect, the condition it 
was used to treat may return even more strongly when the 
drug is discontinued or loses effectiveness”. Also known as 
a “paradoxical reaction” of the organism, this phenomenon 
ironically makes individuals feel with greater intensity and/
or frequency the same symptoms that were expected to 
disappear with the use of medications that exhibited actions 
opposite or contrary (enantiopathic) to the disease symptoms 
and physiological manifestations.
Adverse event (AE) or adverse reaction (AR) is defined by the 
World Health Organization2 (WHO) as “a response to a drug 
which is noxious and unintended, and which occurs at doses 
normally used in man for the prophylaxis, diagnosis, or therapy 
of disease, or for the modification of physiological function”. 
Although the rebound effect is a type of AE with potentially 
severe or even fatal consequences, this effect is scarcely 
disseminated and discussed among health professionals, who 
are thus deprived of crucial knowledge for safe modern drug 
management.
Overall, the rebound effect (paradoxical reaction) is the result 
of the organism’s automatic attempts to return to its basal state 
(homeostasis) after having been altered by the primary effects 
of drugs. Because a characteristic of living beings is their ability 
to maintain a constant internal environment by self-adjusting 
physiological processes, homeostatic mechanisms are present 
at all levels of biological organisation, from simple cell 
mechanisms to the most complex mental functions.
The mechanism that underlies the occurrence of the 
rebound effect is not yet fully elucidated. According to the 
main hypothesis suggested to account for this effect, the 
cause might be an altered regulation and/or response capacity 
of the physiological receptors involved in the drug action 
mechanisms. Experimental evidence has shown that the 
rebound effect occurs at variable time intervals following the 
partial (e.g., dose change, receptor hypersensitivity, treatment 
initiation , tolerance etc.) or complete discontinuation of a 
drug, that the intensity of the ensuing symptoms is greater 
than that of the symptoms initially supressed by the drug, and 
that the duration of action varies.
We have conducted a systemic study on drug rebound 
effects during the last decades in order to establish the grounds 
of the principle of therapeutic similitude (homeopathy) 
vis-à-vis modern pharmacology.3-12 This current updated 
review on the rebound effect aims to direct the attention 
of health professionals to the associated mechanisms, 
consequences, incidence, magnitude, and strategies to avoid 
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the occurrence of this poorly known adverse event that could 
result in severe consequences to the users of several classes 
of drugs, thus contributing to safer modern drug management.
Methods
To increase the body of evidence for and the understanding 
of the rebound effect vis-à-vis clinical and experimental 
pharmacology, an exploratory and qualitative literature review 
was performed in the PubMed database (2002-2012), using the 
keywords ‘rebound’, ‘withdrawal’, ‘paradoxical’, ‘acetylsalicylic 
acid’, ‘anti-inflammatory’, ‘bronchodilator’, ‘antidepressant’, 
‘statin’, ‘proton pump inhibitor’, and ‘bisphosphonate’. The 
articles were selected based on their titles and abstracts, and 
the full texts of those that addressed the investigated subject 
were analysed, as were studies cited by these articles that were 
not detected by the initial survey. The studies considered most 
relevant were included in the present review of the clinical and 
epidemiological features of the rebound effect.
Results
The rebound effect in modern pharmacology
Literature reviews13-15 have described conceptual distinctions, 
evaluation criteria, and scientific evidence for the so-called 
“discontinuation or withdrawal syndromes” of various modern 
drugs (anticoagulants, anticonvulsants, antipsychotics, 
barbiturates, benzodiazepines, cimetidine, clonidine, 
corticosteroids, opiates, propranolol, and antidepressants, 
among others). This “rebound syndrome” is distinguished from 
the “reappearance of the underlying disease” that occurs in the 
absence of pharmacological drug actions, as rebound syndrome 
appears after (partial or complete) drug discontinuation and 
leads to symptoms and/or physiological manifestations 
more intense than those before treatment. Notably, the full 
manifestation of this phenomenon occurs after a given period 
of time that depends on the drugs’ biological effects (time-point, 
or “half-life”). Therefore, gradual discontinuation of a drug is 
recommended to minimize this event.
The following examples illustrate the scope of the 
rebound effects associated with various classes of modern 
drugs.3-12 Drugs for which the primary action promotes 
improvements in angina pectoris (beta-blockers, calcium 
channel blockers, and nitrates, among others) might increase 
the intensity and/or frequency of chest pain following their 
discontinuation. Antihypertensive drugs (alpha-2 adrenergic 
agonists, beta-blockers, angiotensin-converting enzyme 
(ACE) inhibitors, monoamine oxidase (MAO) inhibitors, 
nitrates, sodium nitroprusside, and hydralazine, among 
others) might lead to rebound hypertension following the 
end of their primary biological effects. Antiarrhythmic agents 
(adenosine, amiodarone, beta-blockers, calcium channel 
blockers, disopyramide, flecainide, lidocaine, mexiletine, 
moricizine, and procainamide, among others) might cause 
a rebound exacerbation of baseline ventricular arrhythmias. 
Antithrombotic drugs (argatroban, bezafibrate, heparin, 
salicylates, warfarin, and clopidogrel, among others) might 
promote thrombotic complications as a result of the rebound 
effect. Agents with primary vasoprotective effects (statins) 
might elicit rebound vascular dysfunction that favours the 
occurrence of paradoxical embolism.
Similarly, the discontinuation of psychiatric medication, 
including anxiolytics (barbiturates, benzodiazepines, and 
carbamates, among others), hypnosedatives (barbitura tes, 
benzodiazepines, morphine, promethazine, and zopiclone, among 
others), central nervous system stimulants (amphetamines, 
caffeine, cocaine, mazindol, and methyl phenidate, among 
others), antidepressants (tricyclic antidepres sants, MAO 
inhibitors, and serotonin reuptake inhibitors, among others), 
and antipsychotics (clozapine, phenothiazines, haloperidol, and 
pimozide, among others), might trigger a rebound aggravation 
of the initial clinical condition. Anti-inflammatory agents 
(corticosteroids, ibuprofen, indomethacin, paracetamol, and 
salicylates, among others) might induce a rebound increase 
in inflammation, as well as rebound thrombosis (ibuprofen, 
indomethacin, diclofenac, salicylates, rofecoxib, and celecoxib, 
among others) due to their platelet antiaggregant actions. 
Analgesics (caffeine, calcium channel blockers, clonidine, 
ergotamine, methysergide, opiates, and salicylates, among 
others) might trigger rebound hyperalgesia. Diuretics (furosemide, 
torsemide, and triamterene, among others) might cause rebound 
sodium and potassium retention, with consequent increases in 
the baseline blood volume. Bronchodilators (adrenergic agents, 
disodium cromoglycate, epinephrine, ipratropium, nedocromil, 
salmeterol, and formoterol, among others) might induce 
rebound bronchoconstriction as a paradoxical reaction of the 
organism to treatment discontinuation. Antidyspeptic agents 
(antacids, H2 receptor antagonists, misoprostol, sucralfate, 
and proton-pump inhibitors, among others) might increase 
hydrochloric acid and gastrin secretion as a rebound effect, thus 
aggravating the original clinical condition. Agents used to treat 
osteoporosis (bisphosphonates) might favour the occurrence 
of paradoxical atypical fractures due to a rebound increase in 
osteoclast activity.
Therefore, as demonstrated in clinical and experimental 
pharmacology,3-12 the rebound effect exhibits some particular 
features: (i) it manifests in susceptible individuals; (ii) it is 
independent of the type of drug used or the individual’s disease 
(symptoms); (iii) it appears following partial or complete drug 
discontinuation according to the individual’s idiosyncrasy; 
(iv) it promotes a clinical state opposite to the drug’s primary 
action; (v) the symptoms it induces are more intense than those 
before treatment; and (vi) the effect magnitude is proportional 
to the primary effect of the drug.
In addressing such phenomena, an increasing number 
of studies have indicated the occurrence of “severe” and 
“fatal” adverse events that are associated with the organism’s 
paradoxical reaction.
Rebound effect of platelet antiaggregant drugs
Acetylsalicylic acid
Acetylsalicylic acid (ASA) is a non-steroidal anti-inflammatory 
drug (NSAID) that belongs to the non-selective cyclooxygenase 
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(COX) enzyme inhibitors; these enzymes catalyse the 
conversion of arachidonic acid into prostaglandins (COX-2) 
or thromboxanes (COX-1). ASA is widely used to prevent 
thromboembolism because it inhibits the actions of COX-2 and 
platelet aggregation. Clinical and experimental studies have 
reported the occurrence of rebound thromboembolism 
following the discontinuation of ASA and other platelet 
antiaggregant drugs, which has led to transient ischaemic 
attacks (TIA), acute myocardial infarction (AMI), and stroke in 
susceptible individuals.5,6,16
To assess the risks associated with ASA discontinuation, 
a meta-analysis17 of 50,279 individuals at risk of coronary 
artery disease (CAD) compared “adherence to ASA therapy” 
in CAD prevention and myocardial revascularisation to “ASA 
discontinuation” in the incidence of acute CAD and in the 
implantation of drug-eluting stents. ASA non-adherence/
withdrawal was associated with a 3-fold higher risk of major 
adverse cardiac events (odds ratio (OR) = 3.14; 95% confidence 
interval (95% CI) 1.75-5.61). Another meta-analysis18 
(49,590 individuals) showed that ASA withdrawal preceded 
up to 10.2% of acute cardiovascular syndromes, with intervals 
of 4 to 8 days in the case of acute coronary syndromes, 11 to 
14 days in the case of acute cerebral events, and 18 to 26 days 
in the case of peripheral arterial syndromes.
Compared to treatment maintenance, observational studies 
found a 3 or 4-fold higher risk of severe vascular events 
(AMI, TIA, and stroke) following ASA withdrawal,19-21 while 
4% of such events occurred soon (6  to 30 days) after the 
discontinuation of platelet antiaggregant drugs.22,23
As rebound platelet aggregation was observed after 
the discontinuation of all classes of platelet antiaggregant 
drugs,24-26 both physicians and patients ought to understand 
the appropriate management of such agents to reduce the risk 
of severe and fatal thromboembolic events.
Non-steroidal anti-inflammatory drugs
Similar to ASA, the occurrence of rebound cardiovascular 
events was also observed following the discontinuation of all 
types of NSAIDs (selective and non-selective COX inhibitors). 
Confirming the results of clinical and experimental studies that 
demonstrated the occurrence of rebound platelet aggregation 
after partial or complete NSAID discontinuation,5,6,27,28 a 
systematic review29  of 1.6  million individuals found a 
correlation between the occurrence of cardiovascular 
events and early NSAID treatment (< 30 days); compared 
to non-treatment, rofecoxib use at a doses of ≤ 25 mg/day 
and > 25 mg/day exhibited relative risks (RR) of 1.33 (95% 
CI, 1.00-1.79) and 2.19 (95% CI 1.64-2.91), respectively; while 
diclofenac, meloxicam, and indomethacin exhibited RR of 
1.40 (95% CI, 1.16-1.70), 1.25 (95% CI, 1.00-1.55), and 1.30 (95% 
CI, 1.07-1.60). Another meta-analysis30 of 145,373 individuals 
found a RR of 1.42 (95% CI, 1.13–1.78) for rofecoxib and 1.63 (95% 
CI, 1.12–2.37) for diclofenac.
A case-control study31 that investigated the correlation 
between NSAID use and the risk of hospitalization for AMI 
found similar results for rofecoxib (RR, 1.36; 95% CI, 1.18-1.58), 
diclofenac (RR, 1.40; 95% CI 1.19-1.65), meloxicam (RR, 1.24; 95% 
CI, 1.06-1.45), and indomethacin (RR, 1.36; 95% CI, 1.15-1.61). 
Another case-control study32 found a correlation between 
rofecoxib use and the first AMI event (RR, 1.67; 95% CI, 1.21-2.30). 
These events occurred at an average of 9 (range, 6-13) days 
after treatment initiation; additionally, the risk remained high 
during the first 7 days after rofecoxib discontinuation (RR, 1.23; 
95% CI, 1.05-1.44) and returned to baseline levels between days 
8 and 30 (RR, 0.82; 95% CI, 0.61-1.09), which is characteristic of 
the rebound effect. A retrospective cohort study (1999-2001) 
of 1.4 million rofecoxib users33 found that 8,199 individuals 
(0.58%) suffered AMI while using this drug, and thus this drug 
was withdrawn from the market by the United States Food and 
Drug Administration (FDA).
Recent studies have reported similar results, thus providing 
further evidence of the scope and causality of the rebound 
effect and again calling attention to this type of severe AE.34,35
Rebound effects of bronchodilators
Countless studies conducted over the last decades confirmed 
clinical and experimental findings indicating that “rebound 
bronchoconstriction”, characterized by increased bronchial 
reactivity and asthma aggravation, might occur following the 
partial or complete discontinuation of short and long-acting 
bronchodilators.5,7,36
A major randomised clinical trial (26,355 participants) ended 
prematurely in 2002 after a preliminary analysis pointed to a 
risk of death by asthma among individuals who were treated 
with salmeterol (long-acting beta-agonist (LABA)). The results, 
however, were only published in 200637 and reported the 
occurrence of respiratory-related deaths (RR, 2.16; 95% CI, 
1.06-4.41), asthma-related deaths (RR, 4.37; 95% CI, 1.25-15.34), 
and combined asthma-related deaths or life-threatening 
experiences (RR, 1.71; 95% CI, 1.01-2.89).
A meta-analysis38 of 33,826 individuals with asthma who 
were using LABAs (salmeterol and formoterol) found an 
increase in exacerbations that required hospitalization (OR, 
2.6; 95% CI, 1.6-4.3), life-threatening experiences (OR, 2.1; 95% 
CI, 1.5-3.0), episodes of fatal asthma (OR, 1.8; 95% CI, 1.1-2.9), 
and asthma-related deaths (OR, 3.5; 95% CI, 1.3-9.3). The risk of 
hospitalization did not change despite combining LABA with 
inhaled corticosteroids (OR, 2.1; 95% CI, 1.3-3.4), thus pointing 
to the relevance of the rebound effect.
Also, recent meta-analyses39,40 and a cohort study41 found 
similar results, suggesting that knowledge about the 
paradoxical (rebound) effect and strategies for safe drug use 
should be mandatory.42,43
Rebound effects of antidepressants
Some studies found an increase in depressive symptoms 
following the partial or complete discontinuation of 
antidepressants (including selective serotonin reuptake 
inhibitors (SSRIs)), and related this to a rebound reduction 
of intra-synaptic serotonin (5-hydoxytryptamine (5HT)) levels 
due to a downregulation of the post-synaptic receptors. 
Named in the literature as “serotonin reuptake inhibitor 
discontinuation syndrome”, this syndrome does not depend 
on the length of treatment nor the type of disease and 
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appears at variable timepoints that depend on the half-life 
of each drug.5,8,44-46
Several studies conducted over the last decades have 
addressed increased suicidality (suicidal ideation, attempts, or 
behaviours) among antidepressant users. This severe adverse 
event might be attributed to the rebound effect,8 assuming 
the half-lives of the drugs are taken into account when 
evaluating the phenomenon.47-49 A meta-analysis50 assessed 
the correlation between antidepressant use and suicidality 
in 4,582 paediatric patients and found an RR of 1.66 (95% 
CI, 1.02-2.68) in randomized trials of SSRIs for depression 
treatment and an RR of 1.95 (95% CI, 1.28–2.98) for all 
antidepressants across all indications.
Other meta-analyses found similar results in adolescents51 
and young adults,52 and 1 case-control study53 reported a 
significant risk of suicidality at the onset of treatment, after 
discontinuation, and during periods of dose changes, thus 
addressing the caution required when managing antidepressants.
Rebound effects of cholesterol-lowering drugs (statins)
In addition to reducing cholesterol biosynthesis, statins exhibit 
“pleiotropic” or “vasoprotective” effects that lead to improved 
endothelial function (increased nitric oxide bioavailability, 
inhibition of inflammation and thrombogenic responses, 
immunomodulatory actions, regulation of progenitor cells, 
and stabilization of atherosclerotic plaques). Along with a 
rebound increase in cholesterol production, experimental and 
clinical studies suggest that statin discontinuation induces a 
rebound deterioration of endothelial function (pro-oxidant, 
pro-inflammatory, and pro-thrombotic state), thus maximizing 
the vascular risk.9,54
Interventional55,56 and observational57-63 studies have 
shown that statin discontinuation (rebound effect) is associated 
with a significant increase in the risk of death (due to fatal 
vascular events), compared to maintenance and no treatment. 
A recent retrospective analysis64 of data from 12,689 patients 
with ischaemic stroke showed that statin discontinuation at 
hospital admission was associated with a significantly higher 
risk of death (RR, 2.5; 95% CI, 2.1-2.9) compared to treatment 
maintenance.
Given the increasing evidence on the rebound effects of 
statins, both doctors and patients should be made aware of 
the risks inherent to discontinuation or withdrawal.
Rebound effects of gastric acid suppressants
All types of gastric acid suppressants (antacids, H2 receptor 
inhibitors, and proton-pump inhibitors (PPIs)) induce rebound 
acid hypersecretion. Also, hypergastrinaemia has been 
found to occur as a secondary effect of long-term treatment. 
The rebound effect manifests at a given timepoint after 
discontinuation as a function of the half-life of each particular 
drug.10,65,66
Clinical evidence of rebound acid hypersecretion following 
PPI discontinuation was found in recent interventional 
studies,67-70 in which it affected more than 30% of users.71
Because gastrin exerts trophic actions on several tissues, 
hypergastrinaemia might be associated with the development 
of advanced neoplasia in Barrett’s oesophagus,72 as well as of 
carcinoid tumours in Zollinger-Ellison syndrome and atrophic 
gastritis.73 A cohort study74 found a direct correlation between 
the increased incidence of gastric cancer and PPI use, thus 
suggesting that rebound hypergastrinaemia might represent 
a risk factor for the development of gastric cancer following 
excessive PPI use. Similarly, the increased incidence of gastric 
carcinoid tumours over the past 3 decades (400% among males 
and 900% among females) might also be associated with the 
indiscriminate use of PPIs.75
Although liberal PPI use is recommended in protocols for 
dyspepsia treatment,76 health professionals ought to weigh 
their relative risks and benefits.
Rebound effects of antiresorptive drugs (bisphosphonates)
Bisphosphonates (BPs) promote increased bone mineral density 
(BMD) by inhibiting bone resorption through a reduction in 
osteoclast activity and thus represent the most widely used 
approach to reduce the risk of osteoporosis-related fractures. 
The biological effects (half-life) of BPs remain long after 
discontinuation as a function of their retention in the bone 
matrix. Although BPs do reduce the incidence of the “typical” 
fractures associated with osteoporosis, the occurrence of 
“atypical” subtrochanteric and diaphyseal femoral fractures 
has been recently reported in individuals who use BPs. 
A “rebound osteoclast activity” is believed to be the most likely 
systemic pathogenic mechanism underlying such fractures, 
as these occur independently from trauma and exhibit large 
radiological and clinical alterations, as well as significant 
morbidity.12,77,78
A case series79 and observational studies80-84 found an 
association between BP use over variable periods of time 
(3-60 months) and the occurrence of atypical fractures; a 
putative correlation with cumulative drug use was ruled out, 
as was the hypothesis that suggested hypermineralization 
(osteopetrosis) with microdamage accumulation as the 
pathogenic mechanism.79,85  Additionally, experimental 
studies77,86,87 indicate the occurrence of paradoxical 
osteoclast activity following BP discontinuation (“biphasic 
anti-osteoclastic action”), with rebound increases in markers 
of bone remodelling, eroded areas, and numbers of active 
osteoclasts. Also, other antiresorptive drugs (hormone 
treatments and monoclonal antibodies) were shown to induce 
similar effects.77
Although the incidence of typical hip fractures has 
decreased since the introduction of BPs, the incidence of 
atypical femur fractures has increased,88 thus indicating the 
need for caution when managing such drugs.
Discussion
The rebound effect, a universal and automatic organic 
mecha nism to maintain a constant internal environment or 
homeostasis, is liable to be elicited by all types of enantiopathic 
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drugs. As a function of the drugs’ magnitude, such paradoxical 
reactions might induce severe and eventually fatal adverse 
events. Although the rebound effect only manifests in a very 
small fraction of individuals, it becomes an epidemiological 
concern when considering the exceedingly broad use of 
pharmacological treatments by the population.
The time interval between drug discontinuation and 
rebound effect appearance was similar among drugs with 
short half-lives, with an average of 10 days for ASA, 14 days 
for NSAIDs, 9 days for rofecoxib, 7 to 14 days for SSRIs, 7 days 
for statins, and 7 to 14 days for PIPs. The rebound effect lasted 
up to 30 days for rofecoxib, 21 days for SSRIs, and 30 days for 
PIPs. The length of treatment before discontinuation did not 
correlate with the risk of paradoxical events.
Similar to estimates for other drugs, LABAs cause 1 case 
of fatal rebound bronchospasm per 1,000 patient-years of 
use,38 corresponding to 4,000-5,000 deaths in 2004 in the United 
States alone, and 40,000-50,000 deaths worldwide.7 SSRIs cause 
5 rebound suicidal manifestations per 1,000 patient-years of 
use among adolescents, corresponding to 16,500 cases of 
suicidal ideation or behaviours in 2007 in the United States 
alone.8 BPs cause 1 to 3 episodes of paradoxical atypical 
fractures per 1,000 patient-years of use.12
The literature also addresses the risk of rebound effect 
inherent to the novel agents used in biological therapy,89-91 as 
well as the excessive use of analgesics92 and psychotropic 
drugs.93,94
Upon learning the preliminary results95 of a study23 that 
described the risks associated with ASA discontinuation, 
Richard S. Irwin, then president of the American College of Chest 
Physicians, observed that “this study does not only reinforce 
the importance of compliance with aspirin therapy in coronary 
patients, but it sends a message to all medical professionals 
that the decision to discontinue aspirin therapy should not be 
taken lightly”. Similarly, McColl and Gillen96 address the fact 
that the rebound induction of symptoms by PPIs “means that 
such liberal prescribing is likely to be creating the disease the 
drugs are designed to treat, causing patients with no previous 
need for such therapy to require intermittent or long-term 
treatment”. Similar warnings have also been made regarding 
many of the above-mentioned drugs mentioned, thus indicating 
the relevance of the ability of the rebound effect to induce deep 
alterations to organic homeostasis.
Valuing the rebound phenomenon as a public health 
problem, recent studies have addressed the risks associated 
with the discontinuation of analgesics97,98 and psychotropic 
drugs,46,93,94  which are particularly relevant, given the 
widespread use of such pharmacological agents. Therefore, 
it is worth noting the probable occurrence of the immune 
reconstitution inflammatory syndrome (IRIS) following the 
discontinuation of natalizumab, a monoclonal antibody used 
as a biological therapy for multiple sclerosis, consequent to the 
rebound exacerbation of disease activity.99-102 The advancement 
represented by biological therapy notwith standing, discontinued 
use of immunomodulatory agents is also associated with a high 
frequency of paradoxical reactions in individuals receiving 
cancer treatment.103,104
For the notions described here – which, although orthodox, 
vigorously oppose the therapeutic model – to be widely 
assimilated, we suggest as a pedagogic proposal to include 
corresponding evidence when teaching physiology and 
pharmacology during courses for health professionals, as well 
as during discussions of clinical cases and the follow-up of 
patients who are assisted at hospitals, outpatient clinics, or 
at home.
Professionals at all levels of the healthcare system should be 
systematically aware of and properly oriented to the intrinsic 
dangers associated with the random and abrupt withdrawal 
of drugs so that they might duly advise their patients and 
establish programmes for drug tapering, while closely 
monitoring the subsequent effects.
Regarding scientific research, the studies described in the 
present review might be reproduced in our milieu and thus 
quantify the incidence of the rebound effect, the magnitude 
of its associated risks, and the effectiveness of preventive 
measures. Additionally, a multiplication of the number of 
reported examples will facilitate the admission of the existence 
of the rebound effect by health professionals.
Conclusion
A large number of severe and potentially fatal AE might be 
avoided if health professionals were oriented to recognize 
the occurrence of paradoxical reactions following the 
discontinuation of drugs that exert opposite actions to disease 
manifestations, thus minimizing the occurrence of rebound 
disease aggravation by reducing doses gradually and slowly 
or by restarting the drug. Although these are not traditionally 
considered adverse events, “drug discontinuation effects are 
part of the pharmacology of a drug”,15 and thus should be 
included when teaching modern pharmacology.
In a manner analogous to the homeopathic model of 
treatment that employs drugs that cause changes and 
symptoms similar to those exhibited by the ill individual 
(principle of therapeutic similitude) for more than 2 centuries, 
a novel therapeutic approach known as “paradoxical 
pharmacology” is emerging within modern conventional 
pharmacology. According to that approach, “exacerbating 
a disease might make use of the organism’s compensatory 
and redundant mechanisms to achieve a beneficial long-term 
response”105-109 (use of the bidirectional or biphasic effect).
Paradoxical pharmacology is conventionally associated 
with the use of beta-blockers (beta-adrenoceptor antagonists) 
and calcium channel blockers in congestive heart failure to 
improve ventricular contractility and reducing mortality110,111; 
beta-blockers for chronic asthma treatment to induce 
bronchodilation and reduce airway inflammation112; thiazides 
for diabetes insipidus treatment to reduce polyuria and 
increase urine osmolality due to their paradoxical antidiuretic 
effects113; arsenic trioxide (As2O3), a significant carcinogenic 
agent that has shown promise as a cancer treatment114,115 
(e.g., acute promyelocytic leukaemia); oral contraceptives 
to induce ovulation (and thus pregnancy) in women with 
functional sterility116; central nervous system stimulants 
(amphetamine, methylphenidate, and pemoline, among 
others) for hyperactivity, given the biphasic effects of these 
drugs,117 among other examples. Notably, the doses required 
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to elicit the secondary and curative (paradoxical, rebound, or 
biphasic) effects of these drugs are much lower than those 
usually used to induce their primary effects (avoiding the 
worsening of the disease).
In an attempt to bridge the gap between disparate 
rationalities and to broaden the scope of the therapeutic by 
similars, during the last decade we developed systematics 
for the clinical applications of the rebound curative effects 
of 1,250 modern drugs.118-122 According to this procedure, 
too ill individuals are prescribed drugs that cause adverse 
events similar to their disturbances (totality of symptoms) 
in an attempt to induce a paradoxical reaction of the 
organism against its exhibited disorders (http://www.
newhomeopathicmedicines.com).
While keeping in mind the bioethical principles of 
“beneficence” and “non-maleficence”, physicians should have 
the conviction and sufficient technical information to ensure 
that their actions will benefit patients and cause them the least 
possible harm, according to the Hippocratic aphorism primum 
non nocere. The present review aims to direct our professional 
colleagues’ attention to the occurrence of the rebound effect, 
namely a severe, albeit unknown adverse event of modern 
therapeutics, for the sake of a safer and less iatrogenic clinical 
practice.
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